Search Results - "Laadem, A"

Pharmacokinetics and Exposure–Response Relationship of Luspatercept in Patients with Anemia Due to Lower-Risk MDS: Preliminary Results from Phase 2 Studies by Chen, N, Laadem, A, Wilson, D.M, Zhang, X, Sherman, M.L, Ritland, S, Attie, K.M, Platzbecker, U

Get full text

Luspatercept Response in New Subpopulations of Patients with Lower-Risk Myelodysplastic Syndromes (MDS): Update of the Pace Study by Platzbecker, U, Germing, U, Götze, K, Kiewe, P, Wolff, T, Mayer, K, Chromik, J, Radsak, M, Wilson, D, Zhang, X, Laadem, A, Sherman, M, Attie, K, Linde, P, Giagounidis, A

Get full text

53 LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY by Platzbecker, U, Germing, U, Giagounidis, A, Götze, K, Kiewe, P, Mayer, K, Ottmann, O, Radsak, M, Wolff, T, Haase, D, Hankin, M, Wilson, D, Zhang, X, Laadem, A, Sherman, M, Attie, K

Get full text

14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION by Komrokji, R, Garcia-Manero, G, Ades, L, Laadem, A, Vo, B, Prebet, T, Stamatoullas, A, Boyd, T, Delaunay, J, Steensma, D.P, Sekeres, M.A, Beyne-Rauzy, O, Zou, J, Attie, K.M, Sherman, M.L, Fenaux, P, List, A.F

Get full text

Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients by Cals, L., Rixe, O., François, E., Favre, R., Merad, L., Deplanque, G., Laadem, A., Juin, P., Bereder, J. M., Bernardini, D., Herait, P.

“…Purpose: To determine maximum tolerated dose, safety and efficacy of weekly 24 h infusional 5-fluorouracil (5-FU) combined alternately with oxaliplatin and…”
Get full text

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes by Fenaux, Pierre, Platzbecker, Uwe, Mufti, Ghulam J, Garcia-Manero, Guillermo, Buckstein, Rena, Santini, Valeria, Díez-Campelo, María, Finelli, Carlo, Cazzola, Mario, Ilhan, Osman, Sekeres, Mikkael A, Falantes, José F, Arrizabalaga, Beatriz, Salvi, Flavia, Giai, Valentina, Vyas, Paresh, Bowen, David, Selleslag, Dominik, DeZern, Amy E, Jurcic, Joseph G, Germing, Ulrich, Götze, Katharina S, Quesnel, Bruno, Beyne-Rauzy, Odile, Cluzeau, Thomas, Voso, Maria-Teresa, Mazure, Dominiek, Vellenga, Edo, Greenberg, Peter L, Hellström-Lindberg, Eva, Zeidan, Amer M, Adès, Lionel, Verma, Amit, Savona, Michael R, Laadem, Abderrahmane, Benzohra, Aziz, Zhang, Jennie, Rampersad, Anita, Dunshee, Diana R, Linde, Peter G, Sherman, Matthew L, Komrokji, Rami S, List, Alan F

“…Luspatercept is a fusion protein aimed at binding TGF-β family members and reducing SMAD2 and SMAD3 signaling in patients with myelodysplasia with ring…”
Get full text

Multicenter phase II–III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients by Misset, J.-L., Vennin, Ph, Chollet, Ph, Pouillart, P., Laplaige, Ph, Frobert, J. L., Castera, D., Fabro, M., Langlois, D., Cortesi, E., Lucas, V., Gamelin, E., Laadem, A., Otero, J.

“…Summary Purpose: A phase II–III randomised study to compare safety and efficacy of an oxaliplatin/cyclophosphamide (OXAC) combination, vs. the reference…”
Get full text

1550TiP Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC) by Paz-Ares, L., Johnson, M.L., Girard, N., Hann, C.L., Ahn, M-J., Nishio, M., Godard, J., Laadem, A., Yoshizuka, N., Qian, M., Cheng, B., Rudin, C.M.

Get full text

453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study by Doi, T., Patel, M., Falchook, G.S., Koyama, T., Friedman, C.F., Piha-Paul, S., Gutierrez, M.E., Abdul-Karim, R., Awad, M., Adkins, D.R., Takahashi, S., Kadowaki, S., Cheng, B., Ikeda, N., Laadem, A., Yoshizuka, N., Qian, M., Dosunmu, O., Arkenau, H-T., Johnson, M.L.

Get full text

76P Utilization of g score in early oncology drug development: Impact on study design and early go/no-go decision by He, P., Gambhire, D., Zhou, H., Ma, X., Emura, Y., Laadem, A., Leung, D., Bates, S.E., Fojo, A.T., Rixe, O.

Get full text

Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study by Jorge Cortes, Joseph O. Moore, Richard T. Maziarz, Meir Wetzler, Michael Craig, Jeffrey Matous, Selina Luger, Bimalangshu R. Dey, Gary J. Schiller, Dat Pham, Camille N. Abboud, Muthuswamy Krishnamurthy, Archie Brown, Jr, Abderrahmane Laadem, Karen Seiter

“…Rasburicase is effective in controlling plasma uric acid in pediatric patients with hematologic malignancies. This study in adults evaluated safety of and…”
Get full text

77 - Pharmacokinetics and Exposure–Response Relationship of Luspatercept in Patients with Anemia Due to Lower-Risk MDS: Preliminary Results from Phase 2 Studies by Chen, N., Laadem, A., Wilson, D.M., Zhang, X., Sherman, M.L., Ritland, S., Attie, K.M., Platzbecker, U.

Get full text

A phase II/III study of sotatercept (ACE-011), an activin antagonist, for chemotherapy-induced anemia in patients with metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapy by Raftopoulos, H., Laadem, A., Puccio, M., Knight, R. D.

“…Abstract only…”
Get full text

Abstract P5-20-03: A phase 2, double-blind, randomized, placebo-controlled, dose-finding study of sotatercept for the treatment of patients with chemotherapy-induced anemia and metastatic breast cancer by Auerbach, M, Osborne, CRC, Klesczewski, K, Laadem, A, Sherman, ML, Bianca, R

“…Abstract Background: Sotatercept is a recombinant activin receptor IIA (ActRIIA) ligand trap and is comprised of the extracellular domain of ActRIIA linked to…”
Get full text

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions by Fenaux, Pierre, Platzbecker, Uwe, Mufti, Ghulam J., Garcia-Manero, Guillermo, Buckstein, Rena, Santini, Valeria, Díez-Campelo, María, Finelli, Carlo, Cazzola, Mario, Ilhan, Osman, Sekeres, Mikkael A., Falantes, José F., Arrizabalaga, Beatriz, Salvi, Flavia, Giai, Valentina, Vyas, Paresh, Bowen, David, Selleslag, Dominik, DeZern, Amy E., Jurcic, Joseph G., Germing, Ulrich, Götze, Katharina S., Quesnel, Bruno, Beyne-Rauzy, Odile, Cluzeau, Thomas, Voso, Maria Teresa, Mazure, Dominiek, Vellenga, Edo, Greenberg, Peter L, Hellström-Lindberg, Eva, Zeidan, Amer M., Laadem, Abderrahmane, Benzohra, Aziz, Zhang, Jennie, Rampersad, Anita, Linde, Peter G., Sherman, Matthew L., Komrokji, Rami S., List, Alan F.

“…▪ Introduction: MDS is associated with an erythroid maturation defect, characterized by ineffective erythropoiesis leading to anemia and RBC transfusion…”
Get full text

45 - Luspatercept Response in New Subpopulations of Patients with Lower-Risk Myelodysplastic Syndromes (MDS): Update of the Pace Study by Platzbecker, U., Germing, U., Götze, K., Kiewe, P., Wolff, T., Mayer, K., Chromik, J., Radsak, M., Wilson, D., Zhang, X., Laadem, A., Sherman, M., Attie, K., Linde, P., Giagounidis, A.

Get full text

S143 LUSPATERCEPT INCREASES FETAL HEMOGLOBIN (HBF) LEVELS IN ADULT β‐THALASSEMIA PATIENTS WHO REQUIRE RED BLOOD CELL (RBC) TRANSFUSIONS by Cappellini, M.‐D., Schwickart, M., Hermine, O., Piga, A., Risueño, A., Acar, M., Zinger, T., Laadem, A., Shetty, J., Morison, J., Miteva, D., MacBeth, K., Taher, A.

“…Background: The β‐thalassemias are a group of inherited disorders characterized by absent or reduced production of the β‐globin chains of hemoglobin (Hb),…”
Get full text

Abstract P3-06-33: Effect of trastuzumab-based therapy on serum activin A levels in metastatic breast cancer by Zubritsky, LM, Ali, SM, Leitzel, K, Koestler, W, Fuchs, E-M, Costa, L, Knight, R, Laadem, A, Sherman, ML, Lipton, A

“…Abstract Background: Only half of HER2-positive metastatic breast cancer patients will respond to first-line trastuzumab-containing therapy, but of these, most…”
Get full text

PB2260 THE JOURNEY PRO STUDY: FEASIBILITY AND USER ACCEPTANCE OF A SMARTPHONE APP TO ASSESS THE BURDEN OF ANEMIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), β‐THALASSEMIA (BT), AND MYELOFIBROSIS (MF) by Pariseau, J., Hu, X. H., Mahmoud, D., Glasmacher, A., Hudson, M., Jessent‐Ciaravino, V., Gwaltney, C., Kellen, M., Omberg, L., Snyder, P., Mangravite, L., Laadem, A.

“…Background: Understanding patient (pt) experiences, including disease‐ and treatment‐related symptoms, physical functioning, and other aspects of daily life,…”
Get full text

High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol by Lotz, Jean-Pierre, Curé, Hervé, Janvier, Maud, Asselain, Bernard, Morvan, François, Legros, Michel, Audhuy, Bruno, Biron, Pierre, Guillemot, Maryse, Goubet, Jocelyne, Laadem, Abderrahmane, Cailliot, Christian, Maignan, Christine Le, Delozier, Thierry, Glaisner, Sylvie, Maraninchi, Dominique, Roché, Henri, Gisselbrecht, Christian

“…The aim of our study was to evaluate the impact on time to progression (TTP) and overall survival (OS) of high-dose chemotherapy (HD-CT) over conventional CT…”
Get full text